These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 22139622)

  • 1. A comparison of cinnarizine and transdermal scopolamine for the prevention of seasickness in naval crew: a double-blind, randomized, crossover study.
    Gil A; Nachum Z; Tal D; Shupak A
    Clin Neuropharmacol; 2012; 35(1):37-9. PubMed ID: 22139622
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effects of dimenhydrinate, cinnarizine and transdermal scopolamine on performance.
    Gordon CR; Gonen A; Nachum Z; Doweck I; Spitzer O; Shupak A
    J Psychopharmacol; 2001 Sep; 15(3):167-72. PubMed ID: 11565623
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparison of the efficacy of cinnarizine with scopolamine in the treatment of seasickness.
    Pingree BJ; Pethybridge RJ
    Aviat Space Environ Med; 1994 Jul; 65(7):597-605. PubMed ID: 7945125
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transdermal scopolamine for prevention of motion sickness : clinical pharmacokinetics and therapeutic applications.
    Nachum Z; Shupak A; Gordon CR
    Clin Pharmacokinet; 2006; 45(6):543-66. PubMed ID: 16719539
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Scopolamine patch to prevent seasickness: clinical response vs. plasma concentration in sailors.
    Gil A; Nachum Z; Dachir S; Chapman S; Levy A; Shupak A; Adir Y; Tal D
    Aviat Space Environ Med; 2005 Aug; 76(8):766-70. PubMed ID: 16110693
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety of double-dose transdermal scopolamine.
    Bar R; Gil A; Tal D
    Pharmacotherapy; 2009 Sep; 29(9):1082-8. PubMed ID: 19698013
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of cinnarizine in the prevention of seasickness.
    Doweck I; Gordon CR; Spitzer O; Melamed Y; Shupak A
    Aviat Space Environ Med; 1994 Jul; 65(7):606-9. PubMed ID: 7945126
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Scopolamine bioavailability in combined oral and transdermal delivery.
    Nachum Z; Shahal B; Shupak A; Spitzer O; Gonen A; Beiran I; Lavon H; Eynan M; Dachir S; Levy A
    J Pharmacol Exp Ther; 2001 Jan; 296(1):121-3. PubMed ID: 11123371
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The vestibulo-ocular reflex (VOR) under the influence of cinnarizine.
    Doweck I; Gordon CR; Spitzer O; Melamed Y; Shupak A
    J Vestib Res; 1994; 4(3):215-20. PubMed ID: 7921339
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effects of transdermal scopolamine on simulated ship navigation and attention/reaction time.
    Howland J; Rohsenow DJ; Minsky S; Snoberg J; Tagerud S; Hunt SK; Almeida A; Greece J; Allensworth-Davies D
    Int J Occup Environ Health; 2008; 14(4):250-6. PubMed ID: 19043911
    [TBL] [Abstract][Full Text] [Related]  

  • 11. INM investigations into drugs for seasickness prophylaxis.
    Pingree BJ
    J R Nav Med Serv; 1994; 80(2):76-80. PubMed ID: 7707278
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Three-years' experience of transdermal scopolamine: long-term effectiveness and side-effects.
    Shupak A; Gordon CR; Spitzer O; Mendelowitz N; Melamed Y
    Pharmatherapeutica; 1989; 5(6):365-70. PubMed ID: 2594820
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Central effects of cinnarizine: restricted use in aircrew.
    Nicholson AN; Stone BM; Turner C; Mills SL
    Aviat Space Environ Med; 2002 Jun; 73(6):570-4. PubMed ID: 12056673
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and tolerability of a fixed low-dose combination of cinnarizine and dimenhydrinate in the treatment of vertigo: a 4-week, randomized, double-blind, active- and placebo-controlled, parallel-group, outpatient study.
    Pytel J; Nagy G; Tóth A; Spellenberg S; Schwarz M; Répassy G
    Clin Ther; 2007 Jan; 29(1):84-98. PubMed ID: 17379049
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Scopolamine alone or combined with ephedrine in seasickness: a double-blind, placebo-controlled study.
    Laitinen LA; Tokola O; Gothoni G; Vapaatalo H
    Aviat Space Environ Med; 1981 Jan; 52(1):6-10. PubMed ID: 7011299
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Perspectives on transdermal scopolamine for the treatment of postoperative nausea and vomiting.
    Pergolizzi JV; Philip BK; Leslie JB; Taylor R; Raffa RB
    J Clin Anesth; 2012 Jun; 24(4):334-45. PubMed ID: 22608591
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Republic of Singapore Navy's Scopoderm TTS study: results after 2,200 man-days at sea.
    How J; Lee PS; Seet LC; Tan PK
    Aviat Space Environ Med; 1988 Jul; 59(7):646-50. PubMed ID: 3044323
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of transdermal scopolamine against seasickness: a 3-day study at sea.
    Attias J; Gordon C; Ribak J; Binah O; Rolnick A
    Aviat Space Environ Med; 1987 Jan; 58(1):60-2. PubMed ID: 3814034
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cinnarizine in the prophylaxis of seasickness: laboratory vestibular evaluation and sea study.
    Shupak A; Doweck I; Gordon CR; Spitzer O
    Clin Pharmacol Ther; 1994 Jun; 55(6):670-80. PubMed ID: 8004883
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Transdermal therapeutic system of scopolamine (TTS-S) in the prevention of sea sickness and its mechanism of action].
    Wang E
    Zhonghua Er Bi Yan Hou Ke Za Zhi; 1990 Oct; 25(5):299-302, 319. PubMed ID: 2076342
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.